KCNQ1 and type 2 diabetes mellitus: Gotthardová et al. [39] demonstrated the association between genetic polymorphisms in KCNQ1 and therapeutic responses to DPP-4 inhibitor treatment in 137 T2D patients receiving a daily dose of 100 mg sitagliptin (n = 90) or vildagliptin (n = 47).